Eli Lilly and Company (LLY)vsUFP Technologies Inc (UFPT)
LLY
Eli Lilly and Company
$1,115.70
-0.65%
HEALTHCARE · Cap: $994.92B
UFPT
UFP Technologies Inc
$277.89
+0.18%
HEALTHCARE · Cap: $2.16B
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 12513% more annual revenue ($79.67B vs $631.64M). LLY leads profitability with a 33.5% profit margin vs 11.5%. LLY appears more attractively valued with a PEG of 1.11. LLY earns a higher WallStSmart Score of 76/100 (B+).
LLY
Strong Buy76
out of 100
Grade: B+
UFPT
Buy60
out of 100
Grade: C+
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 79 in profit
Keeps 34 of every $100 in revenue as profit
Strong operational efficiency at 54.2%
Revenue surging 47.7% year-over-year
Earnings expanding 26.2% YoY
Safe zone — low bankruptcy risk
Conservative balance sheet, low leverage
15.1% revenue growth
Earnings expanding 21.3% YoY
Areas to Watch
Premium valuation, high expectations priced in
Elevated debt levels
Trading at 29.4x book value
Premium valuation, high expectations priced in
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 33.5% and operating margin at 54.2%. Revenue growth of 47.7% demonstrates continued momentum.
Bull Case : UFPT
The strongest argument for UFPT centers on Altman Z-Score, Debt/Equity, Revenue Growth. Revenue growth of 15.1% demonstrates continued momentum.
Bear Case : LLY
The primary concerns for LLY are P/E Ratio, Debt/Equity, Price/Book. Debt-to-equity of 1.62 is elevated, increasing financial risk.
Bear Case : UFPT
The primary concerns for UFPT are P/E Ratio, PEG Ratio.
Key Dynamics to Monitor
UFPT carries more volatility with a beta of 1.07 — expect wider price swings.
LLY is growing revenue faster at 47.7% — sustainability is the question.
LLY generates stronger free cash flow (7.8B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
LLY scores higher overall (76/100 vs 60/100), backed by strong 33.5% margins and 47.7% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →UFP Technologies Inc
HEALTHCARE · MEDICAL DEVICES · USA
UFP Technologies, Inc. designs and converts foams, films and plastic materials for the medical, automotive, consumer, electronic, industrial, aerospace and defense markets in the United States. The company is headquartered in Newburyport, Massachusetts.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?